Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stopping ras in its tracks.

Channing J Der1, Terry Van Dyke

  • 1Department of Pharmacology, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA. cjder@med.unc.edu

Cell
|June 2, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.

Cell reports·2026
Same author

Advances in RAS Therapeutics for Pancreatic Cancer.

The New England journal of medicine·2026
Same author

Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer.

bioRxiv : the preprint server for biology·2026
Same author

KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer.

Cancer research·2026
Same author

Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor Resistance.

bioRxiv : the preprint server for biology·2026
Same author

KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment.

Cancer research·2026
Same journal

A viral ORFeome library for systems-level genetic dissection of host-pathogen interactions.

Cell·2026
Same journal

Co-option of lysosomal machinery shapes the evolution of the intracellular photosymbiosis supporting coral reefs.

Cell·2026
Same journal

LEF1 and niche factors determine T cell stemness across chronic diseases.

Cell·2026
Same journal

Recurrent patterns of TOP1-mediated neuronal genomic damage shared by major neurodegenerative disorders.

Cell·2026
Same journal

Four-dimensional molecular mapping from a spatial snapshot reveals the dynamics of hair follicle organogenesis.

Cell·2026
Same journal

Whole-cell particle-based digital twin simulations from 4D lattice light-sheet microscopy data.

Cell·2026
See all related articles

Ras protein interaction with phosphatidylinositol 3-kinase (PI3K) p110alpha is crucial for tumor formation in mouse models. This finding impacts strategies for targeting Ras in cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Ras proteins are key regulators of cytoplasmic signaling networks, influencing cell growth and survival.
  • Aberrant Ras signaling is implicated in various human cancers, making it a significant therapeutic target.

Discussion:

  • Gupta et al. demonstrate that the interaction between Ras and a specific PI3K isoform, p110alpha (PIK3CA), is essential for Ras-mediated tumorigenesis.
  • This interaction is critical for the downstream signaling events that drive tumor development.

Key Insights:

  • The study identifies a specific molecular interaction (Ras-p110alpha) as a critical node in Ras-driven cancer.
  • Targeting the p110alpha isoform of PI3K could be a viable strategy to inhibit Ras-driven tumor formation.

Related Experiment Videos

Outlook:

  • These findings necessitate a re-evaluation of current pharmacological approaches aimed at inhibiting Ras signaling for cancer treatment.
  • Further research into isoform-specific PI3K inhibitors may offer more precise and effective cancer therapies.